GSK (GSK) Expected to Release Quarterly Earnings on Wednesday

GSK (NYSE:GSK) is projected to issue its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to announce earnings of $1.33 per share and revenue of $11.78 billion for the quarter. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

GSK (NYSE:GSK) last announced its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.47 EPS. On average, analysts expect GSK to post $4.78 EPS for the current fiscal year and $5.00 EPS for the next fiscal year.

GSK Price Performance

Shares of NYSE:GSK opened at $50.74 on Monday. The company has a market cap of $102.64 billion, a price-to-earnings ratio of 15.87, a PEG ratio of 2.28 and a beta of 0.33. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The firm has a 50 day simple moving average of $49.59 and a 200 day simple moving average of $51.42. GSK has a one year low of $42.85 and a one year high of $61.69.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were paid a dividend of $0.4515 per share. The ex-dividend date of this dividend was Friday, August 14th. This is a boost from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.6%. GSK’s payout ratio is presently 55.31%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Weiss Ratings lowered GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Barclays reiterated a “sell” rating on shares of GSK in a research report on Monday, September 7th. JPMorgan Chase & Co. reissued a “sell” rating on shares of GSK in a research note on Thursday, October 1st. Berenberg Bank reissued a “buy” rating on shares of GSK in a research note on Tuesday, October 6th. Finally, HSBC restated a “hold” rating on shares of GSK in a report on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $55.33.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.